TransMedics Group, Inc. Common Stock
TMDX
$68.00
+2.83%
TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy through its proprietary Organ Care System (OCS). The company operates in the Medical Devices industry, providing a portable platform that preserves, optimizes, and monitors donor organs in a near-physiologic condition, addressing the limitations of traditional cold storage. As a disruptive innovator and a leader in normothermic organ perfusion, TransMedics is currently at the center of the investor narrative due to its rapid transition to profitability and explosive revenue growth, as evidenced by its latest quarterly results, but faces intense scrutiny following a significant stock price correction in May 2026, which has raised questions about its near-term execution and valuation sustainability.…
TMDX
TransMedics Group, Inc. Common Stock
$68.00
Investment Opinion: Should I buy TMDX Today?
Rating & Thesis: Hold. TMDX presents a high-risk, high-reward proposition best suited for patient investors with a high tolerance for volatility, as the stock is in a state of flux following a catastrophic sell-off that has priced in significant skepticism but not yet confirmed a fundamental breakdown. The analyst consensus leans bullish but lacks specific price targets, reflecting uncertainty.
Supporting Evidence: The recommendation is supported by four key data points: 1) The forward P/E of 17.78x is reasonable for a company with 32% YoY revenue growth, 2) Free cash flow generation of $133.59M TTM provides financial flexibility, 3) The stock is technically oversold, trading just 5% above its 52-week low, and 4) Gross margins remain healthy at 58.11%, indicating pricing power for its OCS platform. However, the elevated PS ratio of 6.83x versus sector peers and the high beta of 2.06 cap the near-term upside.
Risks & Conditions: The two biggest risks are a continuation of the revenue growth deceleration below 25% and further multiple compression from current levels. This Hold rating would upgrade to a Buy if the stock stabilizes above $60 support and the company reports next-quarter revenue growth re-accelerating above 35% YoY. It would downgrade to a Sell if QoQ revenue growth turns negative or if the forward P/E expands back above 25x without a corresponding acceleration in growth. The stock is currently fairly valued to slightly overvalued given the growth deceleration risk, trading at a premium to many medical device peers but a discount to its own hyper-growth history.
Sign up to view all
TMDX 12-Month Price Forecast
The outlook for TMDX is balanced with a tilt towards caution. The explosive growth story has hit a significant speed bump, and the market has violently repriced the stock. The base case of stabilized growth around 28% is most probable, leading to a period of consolidation. The high beta of 2.06 will likely continue to drive exaggerated moves. The stance would upgrade to bullish on confirmation of re-accelerating revenue growth in the next quarter or a successful defense of the $60 support level on high volume. It would turn bearish if the $60 level breaks decisively or if management guidance points to a sub-25% growth runway.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransMedics Group, Inc. Common Stock's 12-month outlook, with a consensus price target around $88.40 and implied upside of +30.0% versus the current price.
Average Target
$88.40
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$54 - $88
Analyst target range
Analyst coverage for TMDX is limited, with only 5 analysts providing estimates, indicating it is a mid-cap stock with specialized institutional interest. The consensus sentiment leans bullish, with recent actions from firms like Piper Sandler, Oppenheimer, Evercore ISI, and Needham maintaining 'Overweight' or 'Buy' ratings, while Stifel and JP Morgan maintain 'Hold' or 'Neutral' stances. The average revenue estimate for the forward period is $1.215 billion, with a tight range between $1.202 billion and $1.236 billion, suggesting strong agreement on the near-term growth trajectory. The implied upside or downside to the average analyst price target cannot be calculated as specific target prices are not provided in the data. The wide dispersion in ratings—from Buy to Hold—coupled with the lack of a published target price range, signals moderate conviction but also uncertainty, particularly following the stock's severe correction. The recent cluster of rating reaffirmations in late February 2026, following earnings, suggests analysts are largely maintaining their positive thesis on the fundamentals despite the price action. The limited coverage and high volatility (beta of 2.06) mean the stock is susceptible to sharp moves on company-specific news and may experience less efficient price discovery than larger, more widely followed peers.
Bulls vs Bears: TMDX Investment Factors
The bull case is anchored in the company's proven ability to achieve explosive revenue growth and a rapid inflection to profitability, supported by strong cash generation and a valuation that has reset to more reasonable levels. The bear case focuses on the alarming deceleration in growth, the non-recurring nature of recent profits, and the stock's extreme volatility and still-premium multiples. Currently, the bearish evidence holds stronger sway, as the dramatic price collapse reflects a market reassessment of the growth sustainability thesis. The single most important tension in the investment debate is whether the Q4 growth deceleration to 32.2% YoY is a temporary blip or the beginning of a trend toward normalized, slower growth rates in a competitive medical device market.
Bullish
- Explosive Revenue Growth & Profitability Inflection: Q4 2025 revenue grew 32.2% YoY to $160.76M, and the company achieved a remarkable net income of $105.38M, translating to a 65.5% net margin. This demonstrates a successful transition from a high-growth story to a profitable enterprise, a key valuation catalyst.
- Strong Cash Generation and Liquidity: The company generated $133.59M in TTM free cash flow and maintains a robust current ratio of 7.14. This strong financial position provides a buffer against market volatility and funds continued R&D and commercial expansion without immediate dilution risk.
- Attractive Forward Valuation Post-Selloff: The forward P/E of 17.78x is significantly lower than the trailing P/E of 21.73x, indicating the market is pricing in continued earnings growth. This multiple represents a dramatic compression from historical peaks (e.g., 311x in Q3 2024), suggesting much of the growth premium has been washed out.
- Analyst Consensus Maintains Bullish Stance: Despite the severe price correction, key firms like Piper Sandler and Needham reaffirmed 'Overweight' or 'Buy' ratings post-earnings. The average forward revenue estimate of $1.215B signals strong institutional confidence in the near-term growth trajectory.
Bearish
- Severe Growth Deceleration in Latest Quarter: Q4 2025 revenue growth decelerated sharply to 32.2% YoY from 49% YoY in Q3 2025. This sequential slowdown raises critical questions about the sustainability of the hyper-growth narrative that has driven the stock's premium valuation.
- Profitability Boosted by One-Time Tax Benefit: The stellar Q4 net income of $105.38M was heavily inflated by an $83.75M income tax benefit. The core operating income was $21.27M, a 13.2% margin, indicating underlying profitability is solid but far less spectacular than headline figures suggest.
- Extreme Volatility and High Beta Risk: With a beta of 2.06, TMDX is more than twice as volatile as the market, as evidenced by its -58.76% maximum drawdown. This magnifies downside risk during market corrections or company-specific setbacks, making it unsuitable for risk-averse investors.
- Elevated Valuation Multiples Despite Crash: Even after the crash, the stock trades at a PS ratio of 6.83x and an EV/EBITDA of 27.72x, which are premium multiples for the medical devices sector. This leaves the stock vulnerable to further multiple compression if growth continues to moderate.
TMDX Technical Analysis
The stock is in a severe and sustained downtrend, having declined 48.12% over the past year and 51.32% over the last three months, culminating in a dramatic 45.57% plunge in the past month alone. Currently trading at $63.20, the price sits just 5% above its 52-week low of $60.11, indicating it is deeply oversold and near a critical technical floor. This positioning suggests the stock is either presenting a significant value opportunity after a massive sell-off or is a 'falling knife' with further downside risk if the fundamental story deteriorates. Recent momentum is decisively negative and has accelerated sharply, with the 1-month decline of 45.57% far exceeding the 1-year loss, signaling a capitulation event likely triggered by a specific catalyst. The stock's beta of 2.06 indicates it is more than twice as volatile as the broader market, which has compounded the downside; for instance, while the SPY gained 5.6% over the past month, TMDX lost 45.57%, resulting in a relative strength reading of -51.17, highlighting extreme underperformance and high idiosyncratic risk. Key technical support is now firmly established at the 52-week low of $60.11, with resistance far above at the 52-week high of $156.00. A breakdown below the $60 support level could trigger another leg down, while any recovery would need to reclaim higher levels to suggest a trend reversal. The extreme volatility, as evidenced by the beta of 2.06 and the maximum drawdown of -58.76%, necessitates a high-risk tolerance for investors considering a position, as price swings are amplified relative to the overall market.
Beta
2.06
2.06x market volatility
Max Drawdown
-58.8%
Largest decline past year
52-Week Range
$60-$156
Price range past year
Annual Return
-45.5%
Cumulative gain past year
| Period | TMDX Return | S&P 500 |
|---|---|---|
| 1m | -39.9% | +4.6% |
| 3m | -48.8% | +8.3% |
| 6m | -48.1% | +12.5% |
| 1y | -45.5% | +25.0% |
| ytd | -44.6% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMDX Fundamental Analysis
Revenue growth remains exceptionally strong but showed a notable sequential deceleration in the most recent quarter. Q4 2025 revenue was $160.76 million, representing a robust 32.2% year-over-year increase. However, this marks a slowdown from the 49% YoY growth seen in Q3 2025 ($143.82M vs. $108.76M in Q4 2024). The revenue trajectory confirms the company's commercial success with its OCS platform, but the deceleration in growth rate is a key metric for investors to monitor going forward. The company has achieved a remarkable transition to profitability, with Q4 2025 net income soaring to $105.38 million, yielding a net margin of 65.5%. This profitability is a significant inflection point from prior quarters of minimal or negative earnings. Gross margin for the quarter was a healthy 58.11%, though it has moderated slightly from the 59.92% trailing-twelve-month figure, indicating potential pressure from product mix or costs. The substantial net income was significantly boosted by a $83.75 million income tax benefit; adjusting for this, operating income was $21.27 million, reflecting an operating margin of 13.2%. The balance sheet and cash flow position appear solid. The company holds a strong current ratio of 7.14, indicating ample liquidity. Free cash flow for the trailing twelve months is a positive $133.59 million, demonstrating the business is generating cash from operations. However, debt-to-equity stands at 0.99, suggesting a balanced but notable level of leverage. Return on equity is exceptionally high at 40.2%, though this is inflated by the large net income in the most recent quarter, and the company's asset turnover of 0.15 indicates it is not yet highly efficient at generating sales from its asset base.
Quarterly Revenue
$160764000.0B
2025-12
Revenue YoY Growth
+0.32%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$133589000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMDX Overvalued?
Given the company's positive net income of $105.38 million in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E is 21.73x, while the forward P/E is notably lower at 17.78x. This gap implies the market expects earnings growth to continue, as the forward multiple prices in higher future profits relative to the current share price. Compared to sector averages, TMDX trades at a significant premium on a Price/Sales basis, with a PS ratio of 6.83x, which is elevated for a medical device company, though this partially reflects its hyper-growth profile and recent profitability inflection. The EV/Sales multiple of 4.00x offers a slightly different perspective by incorporating the company's net debt position. The premium valuation suggests the market has been pricing in expectations for sustained high growth and market leadership in its niche. Historically, the stock's valuation has compressed dramatically alongside its price decline. The current trailing P/E of 21.73x is substantially below its recent historical peaks seen in 2024 (e.g., 311x in Q3 2024) when the company was not yet profitable. This compression indicates the market has shifted from valuing the stock on pure growth potential to a more earnings-based framework. The current multiple is now near the lower end of its observable historical range for profitable periods, suggesting the recent sell-off may have priced out much of the previous growth optimism, leaving room for multiple expansion if execution improves.
PE
21.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -683x~311x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the sustainability of profitability, as Q4's 65.5% net margin was heavily dependent on an $83.75M one-time tax benefit. Core operating margins are a more modest 13.2%. Revenue growth deceleration from 49% to 32.2% YoY sequentially is a major operational red flag, suggesting market saturation or competitive pressures may be emerging sooner than expected. While the balance sheet is strong with a 7.14 current ratio, a debt-to-equity of 0.99 indicates leverage that could pressure cash flow if interest rates remain elevated.
Market & Competitive Risks: The stock's extreme beta of 2.06 means it is highly sensitive to broader market swings, amplifying losses during downturns as seen in its -51.17 relative strength vs. the SPY over the past month. Valuation risk is acute; despite a 45% monthly drop, the forward P/E of 17.78x and PS ratio of 6.83x remain at a premium, leaving the stock exposed to further de-rating if growth falters. Competitive and regulatory risks are inherent in the medical device sector, where technological obsolescence and reimbursement changes could disrupt the OCS platform's adoption.
Worst-Case Scenario: The worst-case scenario involves the Q4 growth deceleration marking the start of a sustained trend, leading to a significant earnings miss in the next quarter. This could trigger a wave of analyst downgrades from the current bullish consensus, combined with the high short interest (short ratio 9.27) fueling a downward spiral. A breakdown below the critical $60.11 support level could see the stock retest levels not seen since its early commercial stages. From the current $63.20, a realistic downside in this adverse scenario could be a further 35-40% decline, targeting the $38-$41 range, which would align with a forward P/E compressing to 10-11x on lowered earnings estimates.
FAQ
The key risks are, in order of severity: 1) Growth Sustainability Risk: Revenue growth decelerated from 49% to 32% YoY sequentially; further slowdown could crush the valuation. 2) Extreme Volatility Risk: A beta of 2.06 means the stock is more than twice as volatile as the market, leading to amplified losses. 3) Profit Quality Risk: Q4's spectacular net income was inflated by an $83.75M one-time tax benefit; core operating profitability is lower. 4) Competitive & Regulatory Risk: As a medical device company, it faces potential reimbursement changes and technological competition that could disrupt its OCS platform adoption.
Our 12-month forecast outlines three scenarios. The Base Case (55% probability) sees the stock trading between $75 and $95, assuming growth stabilizes around 28% YoY. The Bull Case (25% probability) targets $110 to $130, contingent on growth re-accelerating above 35%. The Bear Case (20% probability) warns of a drop to $45 to $60 if growth falls below 20% and the $60 support breaks. The most likely outcome is the Base Case, where the stock recovers modestly from oversold levels but remains well below its former highs as the growth narrative resets.
TMDX is fairly valued to slightly overvalued relative to its near-term growth prospects. Its forward P/E of 17.78x is reasonable for a company growing revenue at 32%, but its Price/Sales ratio of 6.83x is elevated for the medical devices sector. The valuation has compressed dramatically from historical extremes (e.g., trailing P/E over 300x in 2024), but it still carries a growth premium. The market is currently valuing it as a profitable growth company, not a hyper-growth story. It is undervalued only if growth re-accelerates; it is overvalued if the deceleration continues.
TMDX is a speculative buy only for investors with a high risk tolerance and a long-term horizon. The stock has crashed 45% in a month and is deeply oversold, which could present a buying opportunity if the fundamental growth story remains intact. However, the sharp deceleration in revenue growth to 32.2% YoY is a major red flag. Given its high beta of 2.06 and premium valuation (forward P/E 17.78x), it is not a good buy for conservative investors. Aggressive investors might consider a small position if they believe the growth slowdown is temporary and are prepared for further volatility.
TMDX is unsuitable for short-term trading due to its extreme volatility (beta 2.06) and current lack of clear directional catalysts following the crash. It is a candidate only for long-term investment (minimum 3-5 years) by investors who believe in the long-term adoption of its OCS technology and can ignore severe interim price swings. The company is generating positive free cash flow, which supports a long-term hold thesis, but the path will be rocky. There is no dividend, so total return depends entirely on price appreciation, which requires sustained execution over many years.
